The nano-based theranostics for respiratory complications of COVID-19

References

• Abd Ellah NH, Gad SF, Muhammad K, et al. Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. Nanomedicine. 2020;15(21):2085–2102.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–292.
   PubMed Web of Science ®Google Scholar
• Felordi MS, Memarnejadian A, Najimi M, et al. Is there any alternative receptor for SARS-CoV-2? Cell J. 2021;23(2):247–250.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Dreher M, Kersten A, Bickenbach J, et al. The characteristics of 50 hospitalized COVID-19 patients with and without ARDS. Dtsch Arztebl Int. 2020;117(16):271–278.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Qin L, Puah SHJMJA. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. Med J Aust. 2020;213(2):54–56.
   PubMed Web of Science ®Google Scholar
• Hossein-Khannazer N, Shokoohian B, Shpichka A, et al. An update to “novel therapeutic approaches for treatment of COVID-19”. J Mol Med. 2021;99(2):303–310.
   PubMed Web of Science ®Google Scholar
• Hossein-Khannazer N, Shokoohian B, Shpichka A, et al. Novel therapeutic approaches for treatment of COVID-19. J Mol Med. 2020;98(6):1.
   PubMed Web of Science ®Google Scholar
• Ramezankhani R, Solhi R, Memarnejadian A, et al. Therapeutic modalities and novel approaches in regenerative medicine for COVID-19. Int J Antimicrob Agents. 2020;56(6):106208.
   PubMed Web of Science ®Google Scholar
• Hashemian SMR, Aliannejad R, Zarrabi M, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther. 2021;12(1):1–12.
   PubMed Web of Science ®Google Scholar
• Shpichka A, Bikmulina P, Peshkova M, et al. Engineering a model to study viral infections: bioprinting, microfluidics, and organoids to defeat coronavirus disease 2019 (COVID-19). Int J Bioprint. 2020;6(4):302.
   PubMed Web of Science ®Google Scholar
• Whittle JS, Pavlov I, Sacchetti AD, et al. Respiratory support for adult patients with COVID‐19. J Am Coll Emerg Phys Open. 2020;1(2):95–101.
   Google Scholar
• Ferrari M, Santini A, Protti A, et al. Inhaled nitric oxide in mechanically ventilated patients with COVID-19. J Crit Care. 2020;60:150–160.
   Web of Science ®Google Scholar
• Ignarro LJAP. Inhaled nitric oxide and COVID-19. Br J Pharmacol. 2020;177(16):3848–3849.
   Google Scholar
• Adusumilli NC, Zhang D, Friedman JM, et al. Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19. Nitric Oxide. 2020;103:4–8.
   PubMed Web of Science ®Google Scholar
• Cinatl J, Morgenstem B, Bauer G, et al. Treatment of SARS with human interferons. Lancet. 2003;362(9380):293–294.
   PubMed Web of Science ®Google Scholar
• Hao SR, Yan R, Zhang S-Y, et al. Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study. J Zhejiang Univ Sci B. 2020;21(8):628–636.
   PubMed Web of Science ®Google Scholar
• MacLaren G, Fisher D, Brodie DJJ. Preparing for the most critically ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation. JAMA. 2020;323(13):1245–1246.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Hajage D, Lebreton G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. Lancet Respir Med. 2020;8(11):1121–1131.
   PubMed Web of Science ®Google Scholar
• Paliwal P, Sargolzaei S, Bhardwaj SR, et al. Grand challenges in bio-nanotechnology to manage the COVID-19 pandemic. Front Nanotechnol. 2020;2:5.
   Google Scholar
• Campos EV, Pereira AES, de Oliveira JL, et al. How can nanotechnology help to combat COVID-19? Opport Urgent Need. 2020;18(1):1–23.
   Google Scholar
• Vahedifard F, Chakravarthy KJEM. Nanomedicine for COVID-19: the role of nanotechnology in the treatment and diagnosis of COVID-19. Emergent Mater. 2021;4:75-–99.
   PubMedGoogle Scholar
• Kaushik A. Manipulative magnetic nanomedicine: the future of COVID-19 pandemic/endemic therapy. London (UK): Taylor and Francis; 2020.
   Google Scholar
• Varahachalam SP, Lahooti B, Chamaneh M, et al. Nanomedicine for the SARS-CoV-2: state-of-the-art and future prospects. Int J Nanomedicine. 2021;16:539–560.
   PubMed Web of Science ®Google Scholar
• Ladju RB, Pascut D, Massi MN, et al. Aptamer: a potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma. Oncotarget. 2018;9(2):2951–2961.
   PubMedGoogle Scholar
• Ahmadivand A, Gerislioglu B, Ramezani Z, et al. Functionalized terahertz plasmonic metasensors: femtomolar-level detection of SARS-CoV-2 spike proteins. Biosens Bioelectron. 2021;177:112971.
   PubMed Web of Science ®Google Scholar
• Mujawar MA, Gohel H, Bhardwaj SK, et al. Nano-enabling biosensing systems for intelligent healthcare; towards COVID-19 management. Mater Today Chem. 2020;17:100306.
   PubMed Web of Science ®Google Scholar
• Kaushik AK, Dhau JS, Gohel H, et al. Electrochemical SARS-CoV-2 sensing at point-of-care and artificial intelligence for intelligent COVID-19 management. ACS Appl Bio Mater. 2020;3(11):7306–7325.
   PubMedGoogle Scholar
• Yalcin HC, Kaushik A. Support of intelligent emergent materials to combat COVID-19 pandemic. Emergent Mater. 2021;4(1):1–2.
   PubMedGoogle Scholar
• Walensky RP, Walke HT, Fauci ASJJ. SARS-CoV-2 variants of concern in the United States-Challenges and Opportunities. JAMA. 2021;325(11):1037–1038.
   PubMed Web of Science ®Google Scholar
• Gage A, Brunson K, Morris K, et al. Perspectives of manipulative and High-Performance nanosystems to manage consequences of emerging new severe acute respiratory syndrome coronavirus 2 variants. Front Nanatechnol. 2021;3:45.
   Google Scholar
• Qin Z, Peng R, Baravik IK, et al. Fighting COVID-19: integrated micro-and nanosystems for viral infection diagnostics. Matter. 2020;3(3):628–651.
   PubMedGoogle Scholar
• Pison U, Welte T, Giersig M, et al. Nanomedicine for respiratory diseases. Eur J Pharmacol. 2006;533(1–3):341–350.
   PubMed Web of Science ®Google Scholar
• Silva ALDA, Santos RS, Xisto DG, et al. Nanoparticle-based therapy for respiratory diseases. An Acad Bras Ciênc. 2013;85(1):137–146.
   PubMed Web of Science ®Google Scholar
• Muralidharan P, Malapit M, Mallory E, et al. Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine. 2015;11(5):1189–1199.
   PubMed Web of Science ®Google Scholar
• Rothan HA, Byrareddy SNJJ. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.
   PubMed Web of Science ®Google Scholar
• Mehta P, Kadam S, Pawar A, et al. Dendrimers for pulmonary delivery: current perspectives and future challenges. New J Chem. 2019;43(22):8396–8409.
   Web of Science ®Google Scholar
• Weiss C, Carriere M, Fusco L, et al. Toward nanotechnology-enabled approaches against the COVID-19 pandemic. ACS Nano. 2020;14(6):6383–6406.
   PubMed Web of Science ®Google Scholar
• Law SL, Huang KJ, Chou VH, et al. Enhancement of nasal absorption of calcitonin loaded in liposomes. J Liposome Res. 2001;11(2–3):165–174.
   PubMed Web of Science ®Google Scholar
• Itani R, Tobaiqy M, Al Faraj AJT. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics. 2020;10(13):5932–5942.
   PubMed Web of Science ®Google Scholar
• Jyoti K, Pandey RS, Kush P, et al. Inhalable cationic niosomes of curcumin enhanced drug delivery and apoptosis in lung cancer cells. Int J Biol Macromol. 2017;98:50.
   PubMed Web of Science ®Google Scholar
• Chrzanowski W, Kim SY, McClements L, et al. Can stem cells beat COVID-19: advancing stem cells and extracellular vesicles toward mainstream medicine for lung injuries associated with SARS-CoV-2 infections. Front Bioeng Biotechnol. 2020;8:554.
   PubMed Web of Science ®Google Scholar
• Chauhan DS, Prasad R, Srivastav R, et al. Comprehensive review on current interventions, diagnostics, and nanotechnology perspectives against SARS-CoV-2. Bioconjugate Chem. 2020;31(9): 2021–2045.
   PubMed Web of Science ®Google Scholar
• Mehta M, Prasher P, Sharma M, et al. Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): a hypothesis. Med Hypotheses. 2020;144:110254.
   PubMed Web of Science ®Google Scholar
• Mehta PP, Ghoshal D, Pawar AP, et al. Recent advances in inhalable liposomes for treatment of pulmonary diseases: concept to clinical stance. J Drug Delivery Sci Technol. 2020;56:101509.
   Web of Science ®Google Scholar
• De Leo V, Ruscigno S, Trapani A, et al. Preparation of drug-loaded small unilamellar liposomes and evaluation of their potential for the treatment of chronic respiratory diseases. Int J Pharm. 2018;545(1–2):378–388.
   PubMedGoogle Scholar
• Tai TT, Wu TJ, Wu HD, et al. A strategy to treat COVID‐19 disease with targeted delivery of inhalable liposomal hydroxychloroquine: a pre‐clinical pharmacokinetic study. Clin Transl Sci. 2020;14(1):132–136.
   PubMed Web of Science ®Google Scholar
• Fathi S, Oyelere AKJF. Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice? Future Med Chem. 2016;8(17):2091–2112.
   PubMed Web of Science ®Google Scholar
• Gharbavi M, Amani J, Kheiri-Manjili H, et al. Niosome: a promising nanocarrier for natural drug delivery through blood-brain barrier. Adv Pharmacol Sci. 2018;2018:6847971.
   PubMed Web of Science ®Google Scholar
• Moazeni E, Gilani K, Sotoudegan F, et al. Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery. J Microencapsul. 2010;27(7):618–627.
   PubMed Web of Science ®Google Scholar
• Sandoval-Yañez C, Castro Rodriguez CJM. Dendrimers: amazing platforms for bioactive molecule delivery systems. Materials. 2020;13(3):570.
   PubMed Web of Science ®Google Scholar
• de Oliveira Cardoso VM, Moreira BJ, Comparetti EJ, et al. Is nanotechnology helping in the fight against COVID-19? Front Nanotechnol. 2020;2:588915.
   Google Scholar
• Gupta S, Krishnakumar V, Sharma Y, et al. Mesenchymal stem cell derived exosomes: a nano platform for therapeutics and drug delivery in combating COVID-19. Stem Cell Rev Rep. 2020;17(1):1–11.
   Web of Science ®Google Scholar
• Khatri M, Richardson LA, Meulia T, et al. Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. Stem Cell Res Ther. 2018;9(1):1–13.
   PubMedGoogle Scholar
• Zhang Q, Honko A, Zhou J, et al. Cellular nanosponges inhibit SARS-CoV-2 infectivity. Nano Lett. 2020;20(7):5570–5574.
   PubMed Web of Science ®Google Scholar
• Vazquez-Munoz R, Lopez-Ribot JLJC. Nanotechnology as an alternative to reduce the spread of COVID-19. Challenges. 2020;11(2):15.
   Google Scholar
• Jeremiah SS, Miyakawa K, Morita T, et al. Potent antiviral effect of silver nanoparticles on SARS-CoV-2. Biochem Biophys Res Commun. 2020;533(1):195–200.
   PubMed Web of Science ®Google Scholar
• Emerich DF, Thanos CGJE. Nanotechnology and medicine. Expert Opin Biol Ther. 2003;3(4):655–663.
   PubMed Web of Science ®Google Scholar
• Albalawi F, Hussein MZ, Fakurazi S, et al. Engineered nanomaterials: the challenges and opportunities for nanomedicines. Int J Nanomedicine. 2021;16:161–184.
   PubMed Web of Science ®Google Scholar
• Yetisgin AA, Cetinel S, Zuvin M, et al. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020;25(9):2193.
   PubMed Web of Science ®Google Scholar
• Sadique MA, Yadav S, Ranjan P, et al. High-performance antiviral nano-systems as a shield to inhibit viral infections: SARS-CoV-2 as a model case study. J Mater Chem B. 2021;9(23):4620–4642.
   PubMed Web of Science ®Google Scholar
• Rashidzadeh H, Danafar H, Rahimi H, et al. Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): diagnosis, treatment, therapy and future perspectives. Nanomedicine. 2021;16(6):497–516.
   PubMed Web of Science ®Google Scholar
• Jones GW, Monopoli MP, Campagnolo L, et al. No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19. Nanomedicine. 2020;15(24):2411–2427.
   PubMed Web of Science ®Google Scholar
• Vivekanandhan K, Shanmugam P, Barabadi H, et al. Emerging therapeutic approaches to combat COVID-19: present status and future perspectives. Front Mol Biosci. 2021;8:55.
   Web of Science ®Google Scholar
• Al-Ahmady ZS, Ali-Boucetta HJFiN. Nanomedicine and nanotoxicology future could be reshaped post-COVID-19 pandemic. Front Nanotechnol. 2020;2:19.
   Google Scholar
• Singh L, Kruger HG, Maguire GEM, et al. The role of nanotechnology in the treatment of viral infections. Ther Adv Infect Dis. 2017;4(4):105–131.
   PubMed Web of Science ®Google Scholar
• Loutfy SA, Elberry MH, Farroh KY, et al. Antiviral activity of chitosan nanoparticles encapsulating curcumin against hepatitis C virus genotype 4a in human hepatoma cell lines. Int J Nanomedicine. 2020;15:2699–2715.
   PubMed Web of Science ®Google Scholar
• Rasmi Y, Saloua KS, Nemati M, et al. Recent progress in nanotechnology for COVID-19 prevention, diagnostics and treatment. Nanomaterials. 2021;11(7):1788.
   Web of Science ®Google Scholar
• Yayehrad AT, Siraj EA, Wondie GB, et al. Could nanotechnology help to end the fight against COVID-19? Review of current findings, challenges and future perspectives. Int J Nanomedicine. 2021;16:5713–5743.
   PubMed Web of Science ®Google Scholar
• Singh P, Singh D, Sa P, et al. Insights from nanotechnology in COVID-19: prevention, detection, therapy and immunomodulation. Nanomedicine. 2021;16(14):1219–1235.
   PubMed Web of Science ®Google Scholar